Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcelo Pasquini

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
Blood|May 16, 2009
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkAmin M Alousi, Daniel J Weisdorf, Brent R Logan, et al.
British Journal of Haematology|December 6, 2023
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantationLindsay Hammons, Shabi Haider, Andrew J Portuguese, et al.
Translational Psychiatry|January 19, 2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically illJennifer M Knight, Erin S Costanzo, Suraj Singh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Blood and marrow transplant clinical trials network state of the Science Symposium 2014Frederick R Appelbaum, Claudio Anasetti, Joseph H Antin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 21, 2018
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient SettingGuru Subramanian Guru Murthy, Parameswaran N Hari, Aniko Szabo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 23, 2019
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 TrialSergio Giralt, Luciano J Costa, David Maloney, et al.
British Journal of Haematology|March 4, 2020
Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic MicroangiopathyNarendranath Epperla, Ang Li, Brent Logan, et al.
Blood|July 2, 2014
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCTCorey Cutler, Brent Logan, Ryotaro Nakamura, et al.
Haematologica|January 21, 2018
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract diseaseWilliam R Drobyski, Aniko Szabo, Fenlu Zhu, et al.
Transplantation and Cellular Therapy|January 29, 2023
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell TherapiesSarah Nikiforow, Matthew J Frigault, Noelle V Frey, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Blood|May 16, 2009
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkAmin M Alousi, Daniel J Weisdorf, Brent R Logan, et al.
British Journal of Haematology|December 6, 2023
Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantationLindsay Hammons, Shabi Haider, Andrew J Portuguese, et al.
Translational Psychiatry|January 19, 2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically illJennifer M Knight, Erin S Costanzo, Suraj Singh, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Blood and marrow transplant clinical trials network state of the Science Symposium 2014Frederick R Appelbaum, Claudio Anasetti, Joseph H Antin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 21, 2018
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient SettingGuru Subramanian Guru Murthy, Parameswaran N Hari, Aniko Szabo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 23, 2019
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 TrialSergio Giralt, Luciano J Costa, David Maloney, et al.
British Journal of Haematology|March 4, 2020
Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic MicroangiopathyNarendranath Epperla, Ang Li, Brent Logan, et al.
Blood|July 2, 2014
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCTCorey Cutler, Brent Logan, Ryotaro Nakamura, et al.
Haematologica|January 21, 2018
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract diseaseWilliam R Drobyski, Aniko Szabo, Fenlu Zhu, et al.
Transplantation and Cellular Therapy|January 29, 2023
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell TherapiesSarah Nikiforow, Matthew J Frigault, Noelle V Frey, et al.
Pageof 9